Literature DB >> 33976347

DNA repair proteins may differentiate papillary thyroid cancer from chronic lymphocytic thyroiditis and nodular colloidal goiter.

Bahri Evren1, Sami Yılmaz2, Neşe Karadağ3, Ayşe Çıkım Sertkaya4, Ömercan Topaloğlu5, Faruk Kılınç6.   

Abstract

Malignant thyroid lesions are the most common malignancy of the endocrine glands with increasing rates in the last two decades. Papillary thyroid cancer is the most common thyroid malignancy. In our study, we aimed to quantitatively evaluate the levels of DNA repair proteins MSH2, MLH1, MGMT, which are representative blocks of patients diagnosed with papillary carcinoma, chronic thyroiditis, or colloidal goiter. Total or subtotal thyroidectomy material of 90 patients diagnosed with papillary carcinoma, nodular colloidal goiter, or chronic thyroiditis between 2009 and 2012 were retrospectively evaluated. Tissue samples obtained from paraffin blocks were stained with MGMT, MSH2, MLH1 proteins and their immunohistochemistry was evaluated. Prepared sections were examined qualitatively by an impartial pathologist and a clinician, taking into account the staining method under the trinocular light microscope. Although there was no statistically significant difference in MGMT, MSH2, MLH1, follicular cell positivity, staining intensity, and immunoreactivity values, papillary carcinoma cases showed a higher rate of follicular cell positivity, and this difference was more pronounced between papillary carcinoma and colloidal goiter. In the MSH2 follicular cell positivity evaluation, the difference between chronic thyroiditis and colloidal goiter was significant (p = 0.023). The difference between chronic thyroiditis and colloidal goiter was significant in the MSH2 staining intensity evaluation (p = 0.001). The difference between chronic thyroiditis and colloidal goiter was significant in MLH1 immunoreactivity evaluation (p = 0.012). Papillary carcinoma cases were demonstrated by nuclear staining only for MSH2 and MLH1 proteins as opposed to hyperplastic nodules. The higher levels of expression of DNA repair genes in malignant tumors compared to benign tumors are attributed to the functional activation of DNA repair genes. Further studies are needed for DNA repair proteins to be a potential test in the development and progression of thyroid cancer.

Entities:  

Year:  2021        PMID: 33976347      PMCID: PMC8113225          DOI: 10.1038/s41598-021-89403-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  15 in total

1.  Cytophotometric expression of Caspase-3 in papillary thyroid carcinoma in nodular goiter colloid.

Authors:  Luciana Rodrigues Queiroz de Souza; Jurandir Marcondes Ribas-Filho; Osvaldo Malafaia; Nicolau Gregori Czeczko; Carmen Australia Paredes Marcondes Ribas; Glein Dias de Souza; Carlos Hespanha Marinho-Junior
Journal:  Rev Col Bras Cir       Date:  2010-10

2.  High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population.

Authors:  Dae-Young Kang; Kyung-Hee Kim; Jin-Man Kim; Seok-Hyung Kim; Ji-Young Kim; Haing-Woon Baik; Yong-Sung Kim
Journal:  Thyroid       Date:  2007-11       Impact factor: 6.568

3.  CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.

Authors:  Undraga Schagdarsurengin; Oliver Gimm; Henning Dralle; Cuong Hoang-Vu; Reinhard Dammann
Journal:  Thyroid       Date:  2006-07       Impact factor: 6.568

4.  Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours.

Authors:  Ilka Ruschenburg; Beate Vollheim; Jerzy Stachura; Carlos Cordon-Cardo; Monika Korabiowska
Journal:  Anticancer Res       Date:  2006 May-Jun       Impact factor: 2.480

5.  MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis.

Authors:  Meenakshi Sawhney; Nidhi Rohatgi; Jatinder Kaur; Siddhartha D Gupta; Suryanaryana V S Deo; Nootan K Shukla; Ranju Ralhan
Journal:  Oral Oncol       Date:  2006-09-25       Impact factor: 5.337

Review 6.  Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Nancy D Perrier; James D Brierley; R Michael Tuttle
Journal:  CA Cancer J Clin       Date:  2017-11-01       Impact factor: 508.702

7.  Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.

Authors:  Haixia Guan; Meiju Ji; Peng Hou; Zhi Liu; Cuifang Wang; Zhongyan Shan; Weiping Teng; Mingzhao Xing
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

8.  Investigation of DNA repair-related SNPs underlying susceptibility to papillary thyroid carcinoma reveals MGMT as a novel candidate gene in Belarusian children exposed to radiation.

Authors:  Christine Lonjou; Francesca Damiola; Monika Moissonnier; Geoffroy Durand; Irina Malakhova; Vladimir Masyakin; Florence Le Calvez-Kelm; Elisabeth Cardis; Graham Byrnes; Ausrele Kesminiene; Fabienne Lesueur
Journal:  BMC Cancer       Date:  2017-05-12       Impact factor: 4.430

9.  Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.

Authors:  Whitney S Goldner; Trevor E Angell; Sallie Lou McAdoo; Joshua Babiarz; Peter M Sadow; Fadi A Nabhan; Christian Nasr; Richard T Kloos
Journal:  Thyroid       Date:  2019-09-27       Impact factor: 6.568

10.  A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk.

Authors:  Xingjian Lai; Yu Xia; Bo Zhang; Jianchu Li; Yuxin Jiang
Journal:  Oncotarget       Date:  2017-06-27
View more
  1 in total

1.  Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.

Authors:  Pei-Pei Qiao; Kai-Sai Tian; Li-Tao Han; Ben Ma; Cen-Kai Shen; Run-Yu Zhao; Yi Zhang; Wen-Jun Wei; Xiao-Ping Chen
Journal:  Endocrine       Date:  2022-04-02       Impact factor: 3.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.